CD4 and myeloid sarcoma: In the same sense, treatment with 50nM of hrGAS6 dramatically reduced not only IL-17 and IFN-γ, but also IL-22, cMAF, SGK-1, HIF1-α and AHR expression in activated CD4+ T cells from patients with MS (Fig 5M–5S respectively).